Pralsetinib
Pralsetinib | |
---|---|
Term | Pralsetinib |
Short definition | Pralsetinib - (pronounced) (pral-SEH-tih feather) drug used to treat adults with non-small cell lung cancer that carries a RET fusion gene and adults and children 12 years and older with certain types of thyroid cancer, including medullary thyroid cancer, that carry a RET fusion gene or a mutation (change) in RET -Gene. It is used in patients whose cancer is advanced or has spread to other parts of the body. |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
Pralsetinib - (pronounced) (pral-SEH-tih feather) drug used to treat adults with non-small cell lung cancer that carries a RET fusion gene and adults and children 12 years and older with certain types of thyroid cancer, including medullary thyroid cancer, that carry a RET fusion gene or a mutation (change) in RET -Gene. It is used in patients whose cancer is advanced or has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Pralsetinib blocks certain proteins made by the RET fusion gene or the mutated RET gene, which can help prevent cancer cells from growing. It's a type of tyrosine kinase inhibitor. Also called Gavreto
External links
- Medical encyclopedia article on Pralsetinib
- Wikipedia's article - Pralsetinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski